Literature DB >> 6739826

Limb salvage in extremity soft-tissue sarcoma: combined modality therapy.

R V Mantravadi, M J Trippon, M K Patel, M J Walker, T K Das Gupta.   

Abstract

Thirty-two consecutive patients with high-grade soft-tissue sarcoma of an extremity were treated preoperatively with concomitant intra-arterial infusion of Adriamycin (doxorubicin) (10 mg/m2 daily for 10 days) and radiotherapy (2500 rad [25 Gy] in 10 fractions in 2 weeks). En bloc resection was then performed. Postoperatively, depending on the surgical specimen findings, radiotherapy was given to a dose ranging from 5000 rad (50 Gy) in 5 weeks to 6000 rad (60 Gy) in 6 weeks equivalent continuous schedules. No residual tumor was found in 28% of the surgical specimens and only minimal tumor in 41%. A functionally intact limb was preserved in 30 patients (94%). Local recurrence developed in one patient (3%). The actuarial overall survival at three years was 70% and disease-free survival 57%.

Entities:  

Mesh:

Year:  1984        PMID: 6739826     DOI: 10.1148/radiology.152.2.6739826

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities.

Authors:  F Di Filippo; A M Calabrò; A Cavallari; S Carlini; G L Buttini; F Moscarelli; F Cavaliere; L Piarulli; R Cavaliere
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

2.  Vascularized tissue transfer for closure of irradiated wounds after soft tissue sarcoma resection.

Authors:  W J Barwick; J A Goldberg; S P Scully; J M Harrelson
Journal:  Ann Surg       Date:  1992-11       Impact factor: 12.969

3.  (Neo)adjuvant chemotherapy and interdigitated split-course hyperfractionated radiation in high risk soft tissue sarcoma - Results from a large single-institution series.

Authors:  Riikka Nevala; Erkki Tukiainen; Maija Tarkkanen; Tom Böhling; Carl Blomqvist; Mika Sampo
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.